Companies › Myungmoon Pharma.
2 active drug programs in 2 registered trials: 2 Phase 4; Metabolic and endocrine, Gastroenterology; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| CnU capsule Magnesium salt of chenodeoxycholic acid and ursodeoxycholic acid | – | Phase 4 | Cholesterol Cholelithiasis | Nov 2027 |
| CnU capsule 500 mg | – | Phase 4 | Biliary Dyspepsia | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07005752 | CnU capsule | Phase 4 | Cholesterol Cholelithiasis | Metabolic and endocrine | Nov 2027 |
| NCT07016269 | CnU capsule 500 mg | Phase 4 | Biliary Dyspepsia | Gastroenterology | Nov 2027 |
No annotated target.
–
Visirna Therapeutics HK Currax Pharmaceuticals Rivus Pharmaceuticals Xintian Pharmaceutical Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.